Peripheral Artery Disease Clinical Trials

Find Peripheral Artery Disease Clinical Trials Near You

Randomized Clinical Trial, Controlled With Conventional Treatment to Evaluate the Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease. The goal is to assess how well PRGF promotes healing over a six-month period.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients aged at least 18 years

• Diagnosis of type 1 or 2 diabetes

• Presence of one or more ulcers below the malleoli

• Ulcer size ranging from 1 to 25 cm2

• Peripheral Arterial Disease (PAD)

• Meet at least 2 of the following crieria:

• Absence of peripheral pulses at any level on physical examination of lower extremities

• Ankle pressure of 50-90 mmHg

• Finger pressure 30-70 mmHg

• Ankle-branchial index (ABI) 0.5-0.9

• Finger-arm index (FIBI) 0.3-0.7

• Transcutaneous oxygen pressure (TcPO2) 30-59 mmHg

• Degree of infection of the lesion on IDSA/IWGDF scale not greater than 1

• Availability of observation during the study period

• Properly completed patient informed consent

Locations
Other Locations
Spain
Hospital Universitario de Basurto.
RECRUITING
Bilbao
Contact Information
Primary
Aitana Sainz
aitana.sainz@bti-implant.es
+34 945 160 653
Time Frame
Start Date: 2025-11-01
Estimated Completion Date: 2027-05-30
Participants
Target number of participants: 38
Treatments
Experimental: Topical application of Plasma Rich in Growth Factors (PRGF)
The Principal Investigator, or duly delegated qualified personnel, is responsible for the preparation using the KMU10-TPC Kit (BTI Biotechnology Institute, S.L.).
Active_comparator: Conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
Manufacturer: N/A
Sponsors
Leads: Biotechnology Institute IMASD
Collaborators: Hospital de Basurto

This content was sourced from clinicaltrials.gov

Similar Clinical Trials